Drug interactions
Istradefylline + Ruxolitinib
Severity: Moderate
Istradefylline and Ruxolitinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Istradefylline at higher doses can raise exposure to drugs cleared by CYP3A4. Ruxolitinib is a CYP3A4 substrate, so its levels may rise and increase dose-related effects such as cytopenias. The effect is mainly relevant at the 40 mg/day istradefylline dose.
What this interaction means in plain words
Istradefylline and Ruxolitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Istradefylline belongs to Central Nervous System; Ruxolitinib belongs to Oncology.
Why it happens
Istradefylline is a weak CYP3A4 inhibitor at higher doses, reducing the metabolism of ruxolitinib.
What to do
Monitor blood counts and signs of ruxolitinib toxicity when istradefylline 40 mg/day is used, and consider reducing the ruxolitinib dose if toxicity develops.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Istradefylline and Ruxolitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Ruxolitinib
Other interactions of Istradefylline
Frequently asked questions
Can I take Istradefylline with Ruxolitinib?
MediHelp rates the interaction as moderate. Istradefylline and Ruxolitinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Istradefylline at higher doses can raise exposure to drugs cleared by CYP3A4. Ruxolitinib is a CYP3A4 substrate, so its levels may rise and increase dose-related effects such as cytopenias. The effect is mainly relevant at the 40 mg/day istradefylline dose.
How serious is the interaction between Istradefylline and Ruxolitinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and signs of ruxolitinib toxicity when istradefylline 40 mg/day is used, and consider reducing the ruxolitinib dose if toxicity develops.
What other medicines interact with Ruxolitinib?
MediHelp also lists interactions of Ruxolitinib with, for example, Atazanavir, Ceritinib, Chloramphenicol. The full list is on the Ruxolitinib page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
